Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers

Journal of Acquired Immune Deficiency Syndromes

Volumn 42, Issue 1, 2006, Pages 52-60

  Yeh, Rosa F ^a   Gaver, Vincent E ^a   Patterson, Kristine B ^b   Rezk, Naser L ^a   Baxter Meheux, Faustina ^a   Blake, Michael J ^c   Eron Jr , Joseph J ^b   Klein, Cheri E ^d   Rublein, John C ^d   Kashuba, Angela D M ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c CHILDREN S MERCY HOSPITAL   (United States)

^d ABBOTT LABORATORIES   (United States)

Author keywords

Cytochrome P450 enzyme system; Induction; Inhibition; Lopinavir; Pharmacokinetics; Protease inhibitors; Ritonavir

Indexed keywords

AMITRIPTYLINE; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARYLAMINE ACETYLTRANSFERASE; CAFFEINE; CLOZAPINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A; FELODIPINE; FLUMAZENIL; HALOPERIDOL; KETOCONAZOLE; LOPERAMIDE; LOPINAVIR PLUS RITONAVIR; MIDAZOLAM; NEUROLEPTIC AGENT; OLANZAPINE; OMEPRAZOLE; PHYTOMENADIONE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; THEOPHYLLINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VITAMIN K GROUP; WARFARIN; XANTHINE OXIDASE;

ABSENCE OF SIDE EFFECTS; ADULT; AREA UNDER THE CURVE; ARTICLE; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; ENZYME INDUCTION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; OPEN STUDY; PHENOTYPE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RASH;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ARYL HYDROCARBON HYDROXYLASES; BIOLOGICAL MARKERS; CAFFEINE; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DRUG THERAPY, COMBINATION; ENZYME INDUCTION; FEMALE; HIV PROTEASE INHIBITORS; HIV SERONEGATIVITY; HUMANS; INJECTIONS, INTRAVENOUS; INTESTINES; LIVER; MALE; MIDAZOLAM; MIDDLE AGED; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; PYRIMIDINONES; RITONAVIR; SUBSTRATE SPECIFICITY; WARFARIN;

EID: 33745433348     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000219774.20174.64     Document Type: Article

References (71)

1. Piscitelli SC, Gallicano KD. Interactions among drugs for HIV and opportunistic infections. N Engl J Med. 2001;344(13):984-996.
2. Sham HL, Kempf DJ, Molla A, et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother. 1998;42(12):3218-3224.
3. Cvetkovic RS, Goa KL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs. 2003;63(8):769-802.
4. Kaletra Product Information. Abbott Park, IL: Abbott Laboratories; February 2004.
5. Corbett AH, Lim ML, Kashuba AD. Kaletra (lopinavir/ritonavir). Ann Pharmacother. 2002;36(7-8):1193-1203.
6. Kumar GN, Dykstra J, Roberts EM, et al. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: a positive drug-drug interaction. Drug Metab Dispos. 1999;27(8):902-908.
7. Lim ML, Min SS, Eron JJ, et al. Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction. J Acquir Immune Defic Syndr. 2004;36(5):1034-1040.
8. Knoell KR, Young TM, Cousins ES. Potential interaction involving warfarin and ritonavir. Ann Pharmacother. 1998;32(12):1299-1302.
9. Newshan G, Tsang P. Ritonavir and warfarin interaction. AIDS. 1999;13(13):1788-1789.
10. Bertz R, Hsu A, Lam W, et al. Pharmacokinetic interactions between Kaletra (lopinavir/ritonavir of ABT-378/r) and other non-HIV drugs [Poster 438]. Paper presented at: 5th International Congress on Drug Therapy in HIV Infection; 2000; Glasgow, UK.
11. Clarke S, Mulcahy F, Bergin C, et al. Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir. Clin Infect Dis. 2002;34(8):1143-1145.
12. McCance-Katz EF, Rainey PM, Friedland G, et al. The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients. Clin Infect Dis. 2003;37(4):476-482.
13. Stevens RC, Rapaport S, Maroldo-Connelly L, et al. Lack of methadone dose alterations or withdrawal symptoms during therapy with lopinavir/ritonavir. J Acquir Immune Defic Syndr. 2003;33(5):650-651.
14. Kim RB, Wandel C, Leake B, et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 1999;16(3):408-414.
15. Chainuvati S, Nafziger AN, Leeder JS, et al. Combined phenotypic assessment of cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase- 2, and xanthine oxidase activities with the "Cooperstown 5 + 1 cocktail". Clin Pharmacol Ther. 2003;74(5):437-447.
16. Kim JS, Nafziger AN, Gaedigk A, et al. Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe. J Clin Pharmacol. 2001;41(7):715-722.
17. Kashuba AD, Bertino JS Jr, Kearns GL, et al. Quantitation of three-month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2, N-acetyltransferase-2, and xanthine oxidase activity determined with caffeine phenotyping. Clin Pharmacol Ther. 1998;63(5):540-551.
18. Kashuba AD, Bertino JS Jr, Rocci ML Jr, et al. Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam. Clin Pharmacol Ther. 1998;64(3):269-277.
19. Kim MJ, Bertino JS Jr, Gaedigk A, et al. Effect of sex and menstrual cycle phase on cytochrome P450 2C19 activity with omeprazole used as a biomarker. Clin Pharmacol Ther. 2002;72(2):192-199.
20. Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood. 2005;106(7):2329-2333.
21. Smith HT, Jokubaitis LA, Troendle AJ, et al. Pharmacokinetics of fluvastatin and specific drug interactions. Am J Hypertens. 1993;6(11(pt 2)):375S-382S.
22. Vachharajani NN, Shyu WC, Smith RA, et al. The effects of age and gender on the pharmacokinetics of irbesartan. Br J Clin Pharmacol. 1998;46(6):611-613.
23. The Adult AIDS Clinical Trials Group Table for Grading Severity of Adult Adverse Experiences. Available at: http://aactg.s-3.com/members/adulttox.html. Accessed September 8, 2004.
24. Kennedy MJ, Scripture CD, Kashuba AD, et al. Activities of cytochrome P450 1A2, N-acetyltransferase 2, xanthine oxidase, and cytochrome P450 2D6 are unaltered in children with cystic fibrosis. Clin Pharmacol Ther. 2004;75(3):163-171.
25. Grant DM, Tang BK, Kalow W. A simple test for acetylator phenotype using caffeine (1984 Classical Article). Br J Clin Pharmacol. 2004;58(7):S788-S793.
26. Locatelli I, Kmetec V, Mrhar A, et al. Determination of warfarin enantiomers and hydroxylated metabolites in human blood plasma by liquid chromatography with achiral and chiral separation. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;818(2):191-198.
27. Kosten T, Oliveto A, Feingold A, et al. Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients. Drug Alcohol Depend. 2003;70(3):315-325.
28. Kanazawa H, Okada A, Igarashi E, et al. Determination of midazolam and its metabolite as a probe for cytochrome P450 3A4 phenotype by liquid chromatography-mass spectrometry. J Chromatogr A. 2004;1031(1-2):213-218.
29. Rezk NL, Tidwell RR, Kashuba AD. High-performance liquid chromatography assay for the quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;805(2):241-247.
30. Saruwatari J, Nakagawa K, Shindo J, et al. A population phenotyping study of three drug-metabolizing enzymes in Kyushu, Japan, with use of the caffeine test. Clin Pharmacol Ther. 2002;72(2):200-208.
31. Fuhr U, Rost KL, Engelhardt R, et al. Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations. Pharmacogenetics. 1996;6(2):159-176.
32. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics. 2002;12(3):251-263.
33. Balian JD, Sukhova N, Harris JW, et al. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin Pharmacol Ther. 1995;57(6):662-669.
34. Marinac JS, Balian JD, Foxworth JW, et al. Determination of CYP2C19 phenotype in black Americans with omeprazole: correlation with genotype. Clin Pharmacol Ther. 1996;60(2):138-144.
35. Madan A, Graham RA, Carroll KM, et al. Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos. 2003;31(4):421-431.
36. Hsu A, Granneman GR, Witt G. Assessment of multiple doses of ritonavir on the pharmacokinetics of theophylline [abstract Mo.B.1200]. Presented at: XI International Conference on AIDS; 1996; Vancouver, Canada.
37. Penzak SR, Hon YY, Lawhorn WD, et al. Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers. J Clin Psychopharmacol. 2002;22(4):366-370.
38. Takahashi H, Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet. 2001;40(8):587-603.
39. Bajpai M, Roskos LK, Shen DD, et al. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab Dispos. 1996;24(12):1401-1403.
40. Kumar GN, Rodrigues AD, Buko AM, et al. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther. 1996;277(1):423-431.
41. Drug Facts and Comparisons, 58th ed. Wolters Kluwer Health, Inc.; 2004; St. Louis, MO.
42. Gerber JG, Rhodes RJ, Gal J. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality. 2004;16(1):36-44.
43. Gerber JG, Rosenkranz S, Segal Y, et al. Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS Clinical Trials Group (ACTG) 401. J Acquir Immune Defic Syndr. 2001;27(2):153-160.
44. Iribarne C, Dreano Y, Bardou LG, et al. Interaction of methadone with substrates of human hepatic cytochrome P450 3A4. Toxicology. 1997;117(1):13-23.
45. Foster DJ, Somogyi AA, Bochner F. Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4. Br J Clin Pharmacol. 1999;47(4):403-412.
46. Eap CB, Cuendet C, Baumann P. Binding of d-methadone, l-methadone, and dl-methadone to proteins in plasma of healthy volunteers: role of the variants of alpha 1-acid glycoprotein. Clin Pharmacol Ther. 1990;47(3):338-346.
47. Khaliq Y, Gallicano K, Seguin I, et al. Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease. Br J Clin Pharmacol. 2000;50(2):108-115.
48. Bertilsson L, Henthorn TK, Sanz E, et al. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clin Pharmacol Ther. 1989;45(4):348-355.
49. Sakai T, Aoyama N, Kita T, et al. CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. Pharm Res. 2001;18(6):721-727.
50. Kita T, Sakaeda T, Baba T, et al. Different contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitors. Biol Pharm Bull. 2003;26(3):386-390.
51. Furuta T, Shirai N, Sugimoto M, et al. Pharmacogenomics of proton pump inhibitors. Pharmacogenomics. 2004;5(2):181-202.
52. Breyer-Pfaff U, Pfandl B, Nill K, et al. Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes. Clin Pharmacol Ther. 1992;52(4):350-358.
53. Breyer-Pfaff U. The metabolic fate of amitriptyline, nortriptyline and amitriptylinoxide in man. Drug Metab Rev. 2004;36(3-4):723-746.
54. Tanaka E. Update: genetic polymorphism of drug metabolizing enzymes in humans. J Clin Pharm Ther. 1999;24(5):323-329.
55. Yin OQ, Tomlinson B, Waye MM, et al. Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole. Pharmacogenetics. 2004;14(12):841-850.
56. Feng HJ, Huang SL, Wang W, et al. The induction effect of rifampicin on activity of mephenytoin 4-hydroxylase related to M1 mutation of CYP2C19 and gene dose. Br J Clin Pharmacol. 1998;45(1):27-29.
57. Tsunoda SM, Velez RL, von Moltke LL, et al. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Ther. 1999;66(5):461-471.
58. Lown KS, Bailey DG, Fontana RJ, et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest. 1997;99(10):2545-2553.
59. Gorski JC, Jones DR, Haehner-Daniels BD, et al. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther. 1998;64(2):133-143.
60. Carr R, Andre AK, Bertz RJ, et al. Concommitant administration of ABT-378/ritonavir (ABT-378/r) results in a clinically important pharmacokinetic (PK) interaction with atorvastatin (ATO) but not pravastatin (PRA) [abstract 1644]. Presented at: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000; Toronto, Ontario, Canada.
61. Boffito M, Bonora S, Sales P, et al. Ketoconazole and lopinavir/ritonavir coadministration: boosting beyond boosting. AIDS Res Hum Retroviruses. 2003;19(10):941-942.
62. Vishnuvardhan D, Moltke LL, Richert C, et al. Lopinavir: acute exposure inhibits P-glycoprotein; extended exposure induces P-glycoprotein. AIDS. 2003;17(7):1092-1094.
63. Jain AB, Venkataramanan R, Eghtesad B, et al. Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients. Liver Transpl. 2003;9(9):954-960.
64. Ernest CS II, Hall SD, Jones DR. Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther. 2005;312(2):583-591.
65. Weemhoff JL, von Moltke LL, Richert C, et al. Apparent mechanism-based inhibition of human CYP3A in-vitro by lopinavir. J Pharm Pharmacol. 2003;55(3):381-386.
66. Hsu A, Granneman GR, Witt G, et al. Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother. 1997;41(5):898-905.
67. Kashuba AD, Tierney C, Downey GF, et al. Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results. AIDS. 2005;19(2):145-152.
68. Bertz R, Lam W, Hsu A, et al. Assessment of the pharmacokinetic interaction between ABT-378/ritonavir (ABT-378/r) and efavirenz (EFV) in healthy and in HIV+ subjects. Presented at: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000; Toronto, Ontario, Canada.
69. Hsu A, Isaacson J, Brun S, et al. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2003;47(1):350-359.
70. Bertz R, Ashbrenner E, Foit C, et al. Assessment of the steady-state pharmacokinetics of three dosing regimens of saquinavir (400, 600, and 800 mg twice daily) administration as the hard gelatin capsule (HGC) in combination with lopinavir/ritonavir (LPV/r) 400/100 mg BID in HIV-infected adults. Presented at: 5th International Workshop on Clinical Pharmacology of HIV Therapy; 2004; Rome, Italy.
71. Stephan C, Hentig N, Kourbeti I, et al. Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir. AIDS. 2004;18(3):503-508.